In silico-guided drug repurposing: identification of non-competitive inhibitors of Trypanosoma cruzi and Plasmodium falciparum cysteine proteases

BELLERA C.; SALAS-SARDUY E.; TALEVI A.; ALBERCA L.

Mar del Plata

Congreso; Reunión anual de Sociedades Biocientíficas 2019; 2019

SAIC, SAFE, SAB, SAP, NANOMED-ar, AACYTAL, HCS

Abstract/Resumen: Trypanosoma cruzi and Plasmodium falciparum are the etiologic agents of Chagas disease and Malaria, respectively. Cysteine proteases play key roles in the pathogenesis and survival of these parasites, such as cell/tissue penetration, hydrolysis of host or parasite proteins, autophagy, and evasion or modulation of the host immune response, being considered attractive chemotherapeutic targets. Cruzipain (Cz) and Falcipain-2 (FP-2) are two essential cysteine proteases of such organisms. Previously, we have found that methacycline (a member of tetracycline family) is a non-competitive inhibitor of FP-2 (Alberca et al. 2019). In this study our objective has been the characterization of six tetracycline analogues (tetracycline, minocycline, doxycycline, oxytetracycline, chlortetracycline and methacycline) as inhibitors of these cysteine proteases by in silico and in vitro determinations. First, we used bioinformatic tools to predict possible allosteric binding pockets; subsequently, we studied their possible interactions with these proteases by molecular docking simulations. The structures of the enzymes were obtained from the Protein data bank. Finally, we proceed to inhibition studies on the purified enzymes, which confirmed that these family of antibiotics inhibit cysteine proteases in a reversible, non-competitive manner, with Ki values in the mid-micromolar order. Our results provide further evidence on the utility of computational tools as a rational basis for systematic drug repurposing.